Related Experiment Video
Updated: Aug 2, 2026
06:04
Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
Published on: March 6, 2018
[Prostatic cancer developing after transurethral resection of the prostate for benign prostatic hyperplasia]
Hinyokika Kiyo. Acta Urologica Japonica
|March 10, 2001
Summary
Transurethral resection of the prostate (TUR-P) can precede prostate cancer diagnosis. Regular prostate-specific antigen (PSA) monitoring after TUR-P is crucial for early detection of prostate cancer.
Area of Science:
- Urology
- Oncology
- Pathology
Context:
- A retrospective analysis of 319 histopathologically diagnosed prostate cancer cases between January 1993 and June 1998.
- Identified 7 cases (2.2%) where transurethral resection of the prostate (TUR-P) was previously performed for benign prostatic hyperplasia.
- The latency period between TUR-P and prostate cancer diagnosis varied from 22 months to 15 years.
Purpose:
- To investigate the occurrence of prostate cancer following TUR-P.
- To highlight the importance of post-TUR-P monitoring for prostate cancer detection.
Summary:
- All 7 patients diagnosed with prostate cancer post-TUR-P exhibited elevated prostate-specific antigen (PSA) levels (6.4-399 ng/ml).
- Clinical staging at diagnosis included B1 (2 cases), B2 (2 cases), and D2 (3 cases).
- Only one patient had regular follow-up, leading to early diagnosis via needle biopsy due to persistently high PSA.
Impact:
- The findings underscore the necessity of periodic follow-up examinations after TUR-P to detect prostate cancer.
- Prostate-specific antigen (PSA) measurement is identified as a reliable method for monitoring and early detection in this patient cohort.
- Early detection can potentially lead to better management outcomes for patients who develop prostate cancer after TUR-P.
